Intriguingly, our group previously showed that YBX1 overexpression could profoundly activate NF-κB signaling, and may thus serve as a novel therapeutic target for colorectal cancer (CRC) patients in which aberrant NF-κB activity is a major driver of malignancy10, 11. The gene discussed is NFKB1; the disease is colorectal carcinoma.